Cite
Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis.
MLA
Avivi, Irit, et al. “Polatuzumab-Based Regimen or CAR T Cell for Patients with Refractory/Relapsed DLBCL-a Matched Cohort Analysis.” Annals of Hematology, vol. 101, no. 4, Apr. 2022, pp. 755–62. EBSCOhost, https://doi.org/10.1007/s00277-021-04749-9.
APA
Avivi, I., Perry, C., Segman, Y., Amit, O., Bar-On, Y., Katz, O. B., Gold, R., Ribakovsky, E., Avigdor, A., Vainstein, V., Goldschmidt, N., Ringelstein-Harlev, S., Horowitz, N. A., Gutwein, O., Gurion, R., Itchaki, G., Abadi, U., Nemets, A., Sofer, O., & Vezker, M. (2022). Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis. Annals of Hematology, 101(4), 755–762. https://doi.org/10.1007/s00277-021-04749-9
Chicago
Avivi, Irit, Chava Perry, Yafit Segman, Odelia Amit, Yaeli Bar-On, Ofrat Beyer Katz, Ronit Gold, et al. 2022. “Polatuzumab-Based Regimen or CAR T Cell for Patients with Refractory/Relapsed DLBCL-a Matched Cohort Analysis.” Annals of Hematology 101 (4): 755–62. doi:10.1007/s00277-021-04749-9.